Patents Assigned to Sumitomo Pharmaceuticals Company
-
Patent number: 5750686Abstract: A novel .beta.-lactam compound of the formula ?1!: ##STR1## or a pharmaceutically acceptable salt thereof, which shows an excellent antibacterial activity against Gram-positive bacteria, especially against methicillin-resistant staphylococci and methicillin-resistant coagulase-negative staphylococci, and a process for producing the same. R.sub.1, R.sub.2, X, Y, Z are as defined in the specifacation.Type: GrantFiled: December 14, 1995Date of Patent: May 12, 1998Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Makoto Sunagawa, Hiroshi Yamaga, Yoshihiro Sumita
-
Patent number: 5731172Abstract: Disclosed are a recombinant adenovirus bearing a DNA sequence encoding a desired foreign polypeptide, and a hybrid promoter (CAG promoter) comprising a cytomegalovirus enhancer, a chicken .beta.-actin promoter, a rabbit .beta.-globin splicing acceptor and a polyA sequence, a process for production thereof, as well as use thereof for in genetic treatment. The recombinant adenovirus effectively expresses the foreign polypeptide in a wide range of animal cells.Type: GrantFiled: September 8, 1994Date of Patent: March 24, 1998Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Izumu Saito, Yumi Kanegae
-
Patent number: 5714346Abstract: A host-vector system suitable for production of human growth hormone (hGH) and a process for production of hGH using the same are provided. As an hGH expression plasmid, a recombinant DNA wherein a DNA coding for hGH is linked to the 3'-terminal of a DNA containing a promoter region derived from Bacillus brevis is provided, and as a host, especially a mutant Bacillus brevis substantially not exhibiting protease activity to hGH is provided. A microorganism obtained by transforming said host with said hGH expression plasmid efficiently produces hGH when it is cultured.Type: GrantFiled: August 22, 1995Date of Patent: February 3, 1998Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Shigezo Udaka, Tsutomu Kajino, Yoko Saito, Masana Hirai, Yukio Yamada, Fumihiko Hoshino
-
Patent number: 5707994Abstract: The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.Type: GrantFiled: April 19, 1996Date of Patent: January 13, 1998Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Yoshihara Ikeda, Yasuyuki Ueki, Hisakazu Kishimoto, Toshio Nishihara, Yumiko Kamikawa
-
Patent number: 5700470Abstract: A recombinant DNA virus for transfecting an animal cell and bearing a foreign gene and a promoter capable of regulating expression of the foreign gene is completely deleted of the function of E2A gene. The recombinant DNA virus can thus stably transduce the foreign gene into various animal cells, which leads to continuous expression of the foreign gene in the animal cells. The continuous expression of the foreign gene can provide an effective treatment of hereditary disease.Type: GrantFiled: March 12, 1996Date of Patent: December 23, 1997Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Izumu Saito, Yumi Kanegae, Michio Nakai
-
Patent number: 5698232Abstract: An interferon is administered singly or in combination with other pharmacological agents to patients with idiopathic sudden sensorineural hearing loss, whereby the patients are remarkably improved.Type: GrantFiled: November 8, 1996Date of Patent: December 16, 1997Assignees: Sumitomo Pharmaceuticals Company, Ltd., Hoffmann-La Roche Inc., Takeda Chemical Industries, Ltd.Inventors: Shinichi Kanemaru, Hideyuki Fukushima
-
Patent number: 5648359Abstract: There is provided a composition for inhibiting the production or secretion of tumor necrosis factor effective for the treatment of cachexia, septic shock, multiple organ failure, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, osteoarthritis, Behcet disease, systemic lupus erythematosus (SLE), graft versus host disease (GvHD), malaria, acquired immune deficiency syndrome (AIDS), meningitis, hepatitis and Type II diabetes mellitus. The composition comprises a pharmaceutically effective amount of a compound of formula (1).Type: GrantFiled: December 28, 1994Date of Patent: July 15, 1997Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Naohito Ohashi, Norio Fujiwara, Yutaka Ueda
-
Patent number: 5616586Abstract: Tricyclic quinoxalinediones of the formula: ##STR1## wherein X is alkyl, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, etc.; R.sup.1 is H, etc.; R.sup.2 is H, alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkylalkyl, arylalkyl, substituted arylalkyl, aryl, or substituted aryl; W is H, CO.sub.2 R.sup.3, CO.sub.2 Y, CONR.sup.3 R.sup.4, CONR.sup.3 Y, CON(OR.sup.3)R.sup.4, COR.sup.3, CN, tetrazolyl, or substituted alkyl; R.sup.3 and R.sup.4 independently are H, alkyl, cycloalkyl, alkenyl, alkynyl, etc.Type: GrantFiled: April 1, 1994Date of Patent: April 1, 1997Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Ryu Nagata, Norihiko Tanno, Toru Kodo
-
Patent number: 5616618Abstract: Threo-3-(3,4-dihydroxyphenyl)serine exhibits an analgesic effect against acute pains and chronic or continuous pains. Therefore, threo-3-(3,4-dihydroxyphenyl)serine is effective for the treatment of diseases with pains such as postoperative pain, headache, migraine, pains accompanied by rheumatism, post-herpes neuralgia, cancerous pain, pains associated with cervico-omo-brachial syndrome, shoulder periarthritis, spinal distortion, and spondylosis deformans.Type: GrantFiled: July 24, 1995Date of Patent: April 1, 1997Assignee: Sumitomo Pharmaceuticals Company, LimitedInventor: Hiroshi Takagi
-
Patent number: 5532372Abstract: An imide compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which the substituents are defined herein, and n is an integer of 0 to 1;D is a group of the formula:--(CH.sub.2).sub.p --A--(CH.sub.2).sub.q --in which A is a non-aromatic hydrocarbon ring optionally bridged with a lower alkylene group or an oxygen atom, said non-aromatic hydrocarbon ring and said lower alkylene group being each optionally substituted with at least one lower alkyl, and p and q are each an integer of 0, 1 or 2; andAr is an aromatic group, a heterocyclic aromatic group, a benzoyl group, a phenoxy group or a phenylthio group and G is >N--, >CH-- or >COH-- or Ar is a biphenylmethylidene group and G is >C.dbd., all of the above groups being each optionally substituted with at least one of lower alkyl, lower alkoxy and halogen; and its acid addition salts, useful as an antipsycotic agent.Type: GrantFiled: August 30, 1993Date of Patent: July 2, 1996Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Ikutaro Saji, Masayuki Muto, Norihiko Tanno, Mayumi Yoshigi
-
Patent number: 5498447Abstract: A coating method which is characterized in that, when the surfaces of solid particles kept flowing are spray-coated with a thermally melted wax, a two-fluid nozzle adapted to mix a thermally melted wax with a heating gas in and eject the resultant mixture from one flow passage and eject a heating gas from the other flow passage is used, the two-fluid nozzle having spray ports of a diameter of 1.5 to 5.8 mm, and the two-fluid nozzle having no needle valve. According to this method, the use of an organic solvent for melting wax is omitted, and complicated operations for pulverizing a wax and for thermally melting the wax powder after it has been deposed on solid particles are not required. This method can also prevents clogging of the nozzle, powdering of the melted wax and forming of agglomerated solid, and permits simple and easy production of sustained release preparations and preparations for masking materials of unpleasant and bitter tastes.Type: GrantFiled: November 4, 1994Date of Patent: March 12, 1996Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Hiroyuki Nishii, Masaru Kobayashi, Kazutoshi Toya, Nobuo Uchiyama
-
Patent number: 5496843Abstract: A tricyclic indole-2-carboxylic acid derivative represented by the formula 1: ##STR1## wherein X represents alkyl, halogen or cyano;R.sup.1 represents hydrogen, or a protecting group of carboxyl group;W represents hydrogen, --CO.sub.2 R.sup.3i, --CONR.sup.3i R.sup.4i, --A--CO.sub.2 R.sup.3i or --A--CONR.sup.3i R.sup.4i, wherein --A-- represents alkylene and R.sup.3i and R.sup.4i independently represent hydrogen, alkyl, aryl or substituted aryl,or a pharmaceutically acceptable salt thereof, these compounds are selective antagonists of glycine binding site of the NMDA receptor.Type: GrantFiled: November 14, 1994Date of Patent: March 5, 1996Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Ryu Nagata, Norihiko Tanno, Nobuyuki Ae
-
Patent number: 5496559Abstract: A solid formulation for buccal or oral administration which contains a proteinaceous physiologically active substance as an active ingredient, as well as collagen and a water-soluble additive, said formulation being characterized by being porous and having a good disintegration property, and a preparation thereof are provided.Type: GrantFiled: September 30, 1993Date of Patent: March 5, 1996Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Keiji Fujioka, Shigeji Sato, Yoshihiro Takada
-
Patent number: 5385738Abstract: The present invention relates to a sustained-release injection, which comprises a suspension of a powder comprising an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, polysaccharides and synthetic high molecular compounds, preferably collagen, atelocollagen, gelatin, and a mixture thereof) in a viscous solvent for injection (e.g. vegetable oils, polyethylene glycol, propylene glycol, silicone oil, and medium-chain fatty acid triglycerides). The sustained-release injection can release the active ingredient at an effective level for a long period of time when injected.Type: GrantFiled: March 4, 1992Date of Patent: January 31, 1995Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Yoshiya Yamahira, Keiji Fujioka, Shigeji Sato, Yoshihiro Takada
-
Patent number: 5342940Abstract: High purity polyethylene glycol derivatives of formula (I) are useful as protein modifiers of interferons, t-PA, EGF, various hormones, etc. The thus modified protein has minimized antigenicity, prolonged plasma half life, or improved transfer to tissue. A novel process for preparing high purity polyethylene glycol derivatives is also disclosed.Type: GrantFiled: September 13, 1993Date of Patent: August 30, 1994Assignees: Sumitomo Pharmaceuticals Company, Limited, Seikagaku CorporationInventors: Keiichi Ono, Yoshiyuki Kai, Hiroo Maeda
-
Patent number: 5322952Abstract: Pyrrolidine derivatives of the formula (1): ##STR1## wherein R is a protective group of the amino group, intermediates for constructing the 2-positioned side chain of antibacterial penem and carbapenem compounds, are prepared by allowing ##STR2## to react with active esterifying agents in the presence of a base, further allowing the product to react with hydrogen sulfide in the presence of a base and then treating the product with a base.Type: GrantFiled: January 11, 1993Date of Patent: June 21, 1994Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Makoto Sunagawa, Haruki Matsumura, Takashi Bando
-
Patent number: 5278297Abstract: A gene coding for Protein H, which is capable of binding specifically to human IgG of all subclasses, was isolated from Streptococcus sp. AP1 and expressed in host cells, E. coli to produce the Protein H.Type: GrantFiled: October 15, 1992Date of Patent: January 11, 1994Assignees: Sumitomo Pharmaceuticals Company, Ltd., HighTech Receptor ABInventors: Hideyuki Gomi, Tatsunobu Hozumi, Shizuo Hattori, Chiaki Tagawa, Fumitaka Kishimoto, Lars Bjorck
-
Patent number: 5258396Abstract: A novel thiazole derivative represented by the following general formula [1] and a pharmaceutically acceptable salt thereof: ##STR1## wherein A is a single bond, a straight-chained or branched lower alkylene group or a straight-chained or branched lower alkenylene group; B is a single bond or --CO--; R.sup.1 is a carboxy group or --CON(R.sup.7)OR.sup.8 (R.sup.7 and R.sup.8 are independently of each other a hydrogen atom or a lower alkyl group); R.sup.2 is a lower alkyl group; R.sup.3 and R.sup.4 are independently of each other a hydrogen atom, a lower alkyl group or a lower alkoxycarbonyl group; R.sup.5 is a hydrogen atom or a halogen atom; and R.sup.6 is a hydrogen atom, a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a thiol group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a nitro group, an amino group, a substituted amino group, a cyano group, a carboxy group or an acyl group.Type: GrantFiled: April 21, 1992Date of Patent: November 2, 1993Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Hiroaki Masumori, Norihiko Tanno, Ikutaro Saji, Yoshihiko Kimura
-
Patent number: 5252480Abstract: A human monoclonal antibody, which has prophylactic and therapeutic effect to infections diseases caused by Pseudomonas aeruginosa, and the epitope of which is located in the outer core moiety of LPS of the microorganism. A hybridoma producing the human monoclonal antibody, and processes for preparing the antibody and hybridoma are also provided.Type: GrantFiled: May 10, 1989Date of Patent: October 12, 1993Assignees: Sumitomo Chemical Company, Limited, Sumitomo Pharmaceuticals Company, LimitedInventors: Shinichi Yokota, Hiroshi Ohtsuka, Hiroshi Ochi, Hiroshi Noguchi, Masazumi Terashima, Masuhiro Kato
-
Patent number: 5231179Abstract: A compound of the formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each a hydrogen atom, a lower alkyl group, an ar(lower)alkyl group or an aryl group, or R.sub.1 and R.sub.2 may be combined together to form a lower alkylene group and/or R.sub.3 and R.sub.4 are combined together to form a lower alkylene group, or R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may be combined together to form an o-phenylene group, X is a halogen atom and Y is an oxygen atom or a nitrogen atom substituted with lower alkyl or aryl, which is useful as an intermediate in the synthesis of 1.beta.-methylcarbapenem compounds valuable as antibiotics.Type: GrantFiled: April 12, 1991Date of Patent: July 27, 1993Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Shiro Terashima, Yoshio Ito, Takeo Kawabata, Kunikazu Sakai, Tamejiro Hiyama, Yoshikazu Kimura, Makoto Sunagawa, Katsumi Tamoto, Akira Sasaki